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Abstract
Background—Obesity is the second leading cause of preventable death in the US, and is twice as
common among individuals with schizophrenia as the general population.
Methods—Data from the Clinical Antipsychotic Trials of Intervention Effectiveness, a multi-site
trial of antipsychotic pharmacotherapy in 1400 patients with schizophrenia was used to examine the
relationships between body mass index (BMI) and medical costs.
Results—ANCOVA analyses found significant increases in both psychiatric and non-psychiatric
medication costs associated with increasing BMI, and a significant, but smaller, difference in costs
of outpatient medical-surgical service utilization: $41 per month for morbidly obese patients
compared to $26 per month for patients of normal weight (F=2.4, p = 0.04). In multivariable logistic
regression analyses, morbid obesity was associated with significantly increased odds of any
outpatient medical-surgical service costs. When compared to observations of BMI>35, BMI
observations within the normal range (18.5–24.9) were half as likely to be associated with any
outpatient medical-surgical costs (OR 0.53, 95% CI 0.45, 0.63).
Conclusions—In this large sample of persons with schizophrenia, obesity was associated with
increased outpatient general medical service and medication costs even after controlling for
demographic characteristics and medical co-morbidity, but the absolute dollar amount was small.
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Obesity is the second leading cause of preventable death in the United States and a major cause
of morbidity and mortality (1). The costs attributable to overweight and obesity for the entire
US population have been estimated to be $92.6 billion, or 9% of total health care costs (2). The
effects of obesity on health care costs exceed those of smoking or problem drinking (3). Obesity
is a risk factor for diabetes (4), hypertension (5), stroke (6), and cardiovascular disease (7).
Obese patients have been shown to have higher health care costs than normal weight controls,
including more hospitalizations, more outpatient visits, and greater pharmacy costs (8). In one
study, after controlling for age, gender, and chronic disease, a person with a body mass index
(BMI) of 40 kg/m2 consumed $115 more in health care costs per year compared with a person
with a BMI of 25 kg/m2 (9).
The prevalence of obesity among individuals with schizophrenia is 1.5–2.0 times higher than
the general population (10): compared to a prevalence of 30% in the general population (11),
patients with schizophrenia have rates of greater than 40% (10). Among persons with
schizophrenia, obesity is associated with co-morbid hypertension and diabetes and reduced
health-related functioning (12). The life expectancy of persons with schizophrenia is 20%
shorter than that of the general population (13), and their mortality rate appears to be increasing
(14). Cardiovascular disease and other obesity-related medical conditions play an important
role in this increasing mortality rate (15).
Multiple factors contribute to obesity among persons with schizophrenia, including sedentary
lifestyle, poverty, lack of healthy food options, and impaired ability to participate in medical
care. Treatment with first- and second-generation antipsychotic medications can also
contribute to weight gain (16). In randomized controlled trials, the estimated average weight
gain at 10 weeks of active drug treatment has ranged from 0.5–5.0 kg (17). Treatment with
atypical antipsychotic medications can cause a rapid increase in body weight in the first few
months of therapy that may not reach a plateau even after one year of treatment (16).
Schizophrenia is a very costly disease in the US adult population, and chronic medical
conditions increase the annual healthcare costs of patients with schizophrenia. For example,
data from the Medical Expenditure Panel Surveys show that patients with schizophrenia and
hypertension spend on average $3913 per year to treat both chronic conditions, 46% more than
the $2675 they spend on schizophrenia alone (18). The relationship between obesity and health
care costs has not been examined among persons with schizophrenia. The specific aim of this
exploratory study was to examine the extent to which obesity contributes to health care costs
(including costs of inpatient and outpatient psychiatric and medical-surgical services and
medication costs) among persons with schizophrenia, after controlling for severity of medical
illness and physical health status. The study utilized baseline and follow-up data from the
Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial, an NIMH-funded,
multi-site trial of antipsychotic pharmacotherapy, which involved over 1400 patients with
schizophrenia at 57 sites in the US between 2001–2003 (19).
Methods
Study Design
This cross-sectional correlation analysis utilized baseline and follow-up data from the CATIE
trial to examine the association between obesity and health care costs among persons with
schizophrenia. Using the BMI categories adopted by the National Institutes of Health (NHLBI)
and the World Health Organization (WHO), observations were classified as normal weight,
overweight, obese and morbidly obese. Inpatient, outpatient and emergency room service
utilization was documented at each monthly visit over the 18-month study period. ANCOVA
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and multivariable logistic regression analyses were used to examine the relationships between
the categories of BMI and the cost categories over all study time points (adjusting for potential
confounding covariates) (20). A range of potential demographic and clinical confounders of
the relationship between obesity and health care costs were examined, including age, race,
gender, educational level, physical health status and (self-reported) medical co-morbidity.
Sample
The CATIE study was initiated by NIMH to compare the effectiveness of antipsychotic
medications. Subjects were adult patients (age 18 to 65 years old) with a diagnosis of
schizophrenia. Patients or their guardians provided written informed consent for the
randomized clinical trial. Potential subjects were excluded if they had a diagnosis of
schizoaffective disorder, mental retardation or other cognitive disorders; first episode of
schizophrenia; past adverse reaction to a proposed treatment; treatment-resistant
schizophrenia; an unstable or serious medical condition; or if they were pregnant or
breastfeeding. The study was conducted from January 2001 through December 2004. The
CATIE study was approved by the institutional review boards (IRB) at each of the 57 sites.
The current study was approved by the IRB of the VA Connecticut Healthcare System.
Definition of terms
Body Mass Index (BMI)
Study analyses evaluated the association between BMI category and health care costs. The
units used in the a nalyses were BMI observations. Baseline BMI was calculated from the
baseline height and weight data, and follow-up BMI was calculated for every time point that
weight data was collected during the 18-month study period (months 1, 3, 6, 9, 12, 15, and 18).
Using the BMI categories adopted by the NHLBI and WHO (21–22), BMI levels were
categorized as normal weight (BMI 18.5–24.9); overweight (BMI 25.0–29.9); obese (BMI
30.0–35.0), and morbidly obese (BMI >35.0).
Health care costs
These analyses evaluated direct health care costs, including costs of medication and of
psychiatric and medical-surgical services. The following categories of health care costs were
evaluated: outpatient mental health services, inpatient psychiatric services, outpatient medical-
surgical services, inpatient medical-surgical services, study-associated (antipsychotic)
medications, ancillary medications, and the total of all of these costs. Indirect costs, such as
lost productivity (employment earnings) were not evaluated.
Service use was documented every month through a self-report questionnaire that recorded
four kinds of inpatient hospital days (medical, surgical, psychiatric and substance abuse) across
six different types of facilities (state mental hospitals, private psychiatric hospitals, VA
hospitals, non-federal general hospitals, community mental health centers, and detoxification
facilities). Use of 16 types of outpatient mental health services, including psychiatric and
psychosocial rehabilitation services were recorded, along with eight different types of medical
outpatient visits and the use of both psychiatric and medical emergency room services (20).
Costs of service utilization were estimated by multiplying the number of units of each type of
health service received by the estimated local unit cost of each service, and then summing the
products to reflect the total health care costs. Unit costs were estimated from published data
and analysis of insurance claims files, and administrative data. Unit costs estimated for each
type of service were derived from published sources from each of the 24 states in which CATIE
sites were geographically located. Where only national unit cost estimates were available, they
were adjusted for state wage rates (23). Cost estimates were derived from published sources
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documenting inpatient costs in the various sectors in each state (24), and substance abuse
treatment costs (25). Unit costs of some services were estimated using claims data from the
2002 MarketScan® dataset (26), a compilation of all mental health and medical insurance
claims from over 500,000 private sector mental health service users, classified by diagnosis
and CPT code. Some unit cost estimates were derived from VA administrative files (27–29).
Unit costs estimated form published reports and public databases were not specific to the
agencies delivering the services at each site. Estimates of service use were based on self-report
and could not be independently evaluated. Faulty recall of service use, however, was minimized
by frequent assessments and by probing on many different types of service.
There were two categories of medication costs in the CATIE study: study-associated
antipsychotic medications which were controlled by study enrollment, and ancillary (all other)
medications which were not controlled by the study. Costs of the ancillary non-psychiatric
medications were based on average daily medication costs for specific agents in the 2002
MarketScan® dataset. Subjects did not incur costs from monthly study visits or study-
associated laboratory assessments.
Medical Co-morbidity
The medical co-morbidity variable used for analyses was a simple count of self-reported
medical diagnoses. Medical disorders reported by participants during the baseline interview
were categorized into medical diagnoses according to the Medical Dictionary for Regulatory
Activities (MedDRA). MedDRA is an international medical terminology which classifies
medical information; it is used extensively throughout the development and regulatory cycles
of pharmaceutical products and biomedical devices (30).
Physical Health Status
Physical health status was measured by the Physical Component Summary Scale (PCS) of the
SF-12, the12-item questionnaire from the Medical Outcomes Study (31). Scores on the SF-12
can range from 0–100, with higher scores reflecting better physical health status. These scores
have been standardized for the general population, such that a score of 50 reflects an average
level of physical health, and each 10-point change in score reflects one standard deviation
(31).
Analyses
The analyses for this exploratory study were conducted in three stages. The first stage involved
the examination of bivariate correlations both between BMI category and demographic and
clinical characteristics, and also between BMI category and the categories of health care costs
over the previous month.
Second, ANCOVA was used to examine the relationships among the categories of BMI and
the cost categories over all time points in which BMI was obtained (weight was measured). As
the aim of this study was to generate, not test, hypotheses, a value of (p<0.05) was used for
statistical significance, with no adjustment for multiple comparisons. As medication costs were
normally distributed, mean monthly costs were evaluated. Costs of inpatient service use were
highly skewed, but showed an approximately log-normal distribution. Consequently, statistical
comparisons of inpatient (and therefore total) cost date were performed using a log
transformation of observed cost data.
Only 28.6% of the BMI observations were associated with any outpatient medical-surgical
costs—i.e., for 71.4% of observations, there were no outpatient medical-surgical costs in the
previous month. Therefore, the third analysis was a logistic regression analysis evaluate
whether overweight and obesity (BMI > 25) were associated with an increased likelihood of
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outpatient medical-surgical costs. For the ANCOVA and logistic regression analyses,
adjustment was made for potentially confounding covariates: demographic characteristics (age,
race, gender); medical co-morbidity (a count of medical conditions); and physical health status
(SF-12 PCS). All data analyses were conducted using the SAS software version 9.1 (SAS
Institute Inc., Cary NC).
Results
The demographic characteristics of the CATIE sample, presented in Table 1, have been
described previously (32). The sample of 1,460 subjects had a mean age of 40.6 (s.d. +/−
11.1),and was 74% male and 35% African-American. Subjects had, on average a mean of 2.2
(s.d. +/− 2.4) medical conditions. The mean physical functioning score on the SF-12 (PCS) for
the sample was 48.6 (s.d. +/− 10.1), which is lower than 50, the normative mean for the general
population (27). Mean BMI (at baseline) was 30.4 kg/m2 (s.d. +/−7.0), with a range of 15.6 –
65.8. kg/m2).
Mean monthly total health care costs over the 18-month study period were $1726 per month
(Table 2). Bivariate analyses revealed that total health care costs were statistically significantly
correlated with BMI category (rho =0.04, p =0.0003), and that outpatient medical-surgical
costs also increased with increasing BMI category (rho= .08, p<0.0001). While statistically
significant, the magnitude of these correlations was small. Other covariates significantly
associated with higher BMI category included (female) gender, (black and Hispanic) race,
increased medical co-morbidity, and poor physical health status,.
In ANCOVA analyses, after adjusting for demographic and clinical characteristics that were
significant in bivariate analyses (including medical co-morbidity), higher BMI category was
significantly associated with mean monthly costs of both study and ancillary medications, and
of outpatient medical-surgical service use (Table 2). Higher BMI was associated with increased
dose (number of capsules) of study (antipsychotic medication) (data not shown). Given the
relatively low monthly outpatient medical-surgical costs of the study sample, the dollar amount
of the differences was small: $41.38 per month for morbidly obese patients compared to $25.78
per month for subjects of normal weight (F=2.4, p = 0.04). Mean monthly costs of inpatient
service utilization and total health care costs were not significantly associated with BMI
category. Log-transformed inpatient and total costs were statistically significantly associated
with BMI category, but there was not a monotonic linear trend of increasing cost with
increasing BMI category in either case. There was no statistically significant difference in mean
monthly costs of outpatient or inpatient mental health services.
Only 28.6% of the BMI observations were associated with any outpatient medical-surgical
service utilization. A multivariable logistic regression analysis was conducted to evaluate
whether obesity was associated with increased odds of any medical-surgical service use,
controlling for age, gender, race, medical co-morbidity, and physical health status. In this
analysis, morbid obesity (BMI >35) was associated with an increased likelihood of any
outpatient medical-surgical service costs. When compared to observations of BMI > 35, BMI
observations within the normal range (18.5–24.9) were half as likely to be associated with any
outpatient medical-surgical costs (OR 0.53, 95% CI 0.45, 0.63). Similarly, BMI observations
in the other two categories (overweight and obese) also had statistically significantly lower
odds of any outpatient medical-surgical costs, when compared to observations of BMI >35.
The odds ratio for overweight (BMI 25.0–29.9) was 0.62 (95% CI 0.54, 0.72); and the odds
ratio for obesity (BMI 30–35.0) was 0.72 (95% CI 0.62, 0.83), when compared to observations
of morbid obesity (BMI >35).
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In this large sample of persons with schizophrenia, obesity was associated with increased health
care costs even after controlling for medical co-morbidity. The most significant differences in
health care costs across BMI categories were in costs of medications, both study-associated
(antipsychotic) medications and ancillary medications, including those used to treat chronic
medical conditions. The difference in the costs of these ancillary medications for morbidly
obese subjects compared to normal weight subjects was about $700 per year (mean monthly
costs of $105 compared to $47). These findings are consistent with previous literature
demonstrating that, over relatively short time frames (such as the 18-month CATIE study
period), the increased costs of medical care are primarily due to medication costs (9). While it
might be expected that costs of non-psychiatric medication would be higher among overweight
and obese patients, it is a bit surprising that the costs of study-associated antipsychotic
medications were also higher. Further analyses revealed that the mean dose of study medication
increased with increasing BMI category, but these analyses cannot determine the direction of
the relationship. It is possible that either obese subjects received higher doses of (antipsychotic)
medications, or that subjects receiving higher doses gained more weight.
With log transformation, total health care costs were associated with BMI, but there was not
a monotonic linear trend of increasing costs with increasing BMI. This suggests a fairly weak
effect of obesity on total health care costs among patients with schizophrenia. There are a
number of factors that determine health care costs in this clinically complex population, but in
this study, total costs were driven mainly by inpatient psychiatric service utilization. It is
important, though, that increasing BMI was statistically significantly associated with increased
outpatient medical-surgical service utilization costs, even after controlling for demographic
characteristics and medical co-morbidity. The percentage increase in costs (25%) is consistent
with previous published reports of costs of obesity in the general population (33), but the
absolute dollar amount in this study was quite small, dwarfed by the costs attributable to
medications and inpatient psychiatric service utilization.
The lack of a larger effect of BMI on medical-surgical service utilization costs may reflect
some limitations of this study. First, the time frame of the CATIE study was 18 months, which
may not be long enough to capture the medical costs associated with obesity, in particular
inpatient medical costs. Second, in order to evaluate an independent association between
obesity and costs, analyses controlled for medical co-morbidity. The method of evaluating co-
morbidity (a count of self-reported illnesses) has limitations, as self-report may be particularly
problematic among persons with schizophrenia, and a simple count of diagnoses may not
perform as well as other more complex indices. Moreover, controlling for medical co-morbidity
may underestimate the true relationship between obesity and medical costs, as a large
proportion of medical costs are attributable to obesity-related conditions, such as diabetes. In
one large study of the costs associated with obesity, five obesity-related diseases (hypertension,
dyslipidemia, diabetes, coronary artery disease, and stroke) accounted for approximately 85%
of the economic burden of obesity (9). This was not the case in this sample. To address this
question, the ANCOVA analysis of outpatient medical –surgical costs was repeated without
controlling for medical co-morbidity. While the difference between morbid obesity and the
other BMI categories was more robust (F=15.36, p<0.0001), the magnitude of differences in
the costs was not large (normal weight $21 per month; morbid obesity $34 per month).
Finally, and perhaps most importantly, it may be difficult to see a large effect of obesity on
outpatient medical-surgical costs because these costs were small among CATIE subjects.
Subjects in the CATIE study were relatively young (mean age 40.6), and the findings of an
association between obesity and health care costs may have been more robust in an older
sample. Also, subjects in the CATIE study had frequent (monthly) study visits, which may
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have decreased their utilization of medical services, in particular emergency room services.
Moreover, despite intense efforts to include a broad range of subjects in the CATIE trial, some
individuals who may have had particularly high health care costs were excluded form the study:
those with serious or unstable medical conditions, cognitive disorders, or treatment-resistant
schizophrenia.
These small costs of outpatient medical-surgical service utilization, however, do not appear to
be explained by a lack of need for medical care, as subjects had, on average, more than two
chronic medical conditions. It is more likely that this reflects an under-utilization of necessary
medical care by persons with serious mental illness, as has been reported by previous studies
(34). The current study identified an association between obesity and increasing costs
associated with chronic medical illness (medications and outpatient medical-surgical service
use) among persons with schizophrenia, which were small in magnitude. Future research
should examine health care costs over longer time periods, and the indirect costs of obesity in
this population.
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Table 1
Baseline Demographic and Clinical Characteristics of CATIE Subjects (n=1460).
Characteristic Mean +/− standard deviation or Number (%)
Demographics








Spanish, Hispanic, or Latino ethnicity –number (%) 170(12)




Never married 868 (59)
Unemployed—number (%)1 1217 (85)
Clinical characteristics
Years since first antipsychotic medication prescribed 14.4+/−10.7
Baseline medical diagnoses—number 2.2 +/− 2.4
Specific medical diagnoses--number (%) 154(11)




Percentage based on the number of patients with data available (n=1435)
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